Pulmonary Arterial Hypertension
Conditions
Keywords
Pulmonary Arterial Hypertension, Selexipag, Real World Data, Effectiveness
Brief summary
This is an observational, ambrispective study of patients in real world clinical practice, who has pulmonary arterial hypertension in whom a prostacyclin IP receptor agonist (Selexipag) is initiated between 2017 and 2021. The aim of this study answer the following questions: * Changes in the mortality risk profile of these patients after treatment administration. * Baseline characteristics of patients initiating Selexipag. * Parameters used for risk stratification prior to treatment escalation. * Events during follow-up. No comparison group available
Interventions
Real life drug evaluation
Sponsors
Hospital Universitario Virgen Macarena
Hospital Regional de Malaga
Hospital Universitario Virgen de la Victoria
Hospital San Juan de la Cruz
Complejo Hospitalario de Especialidades Juan Ramón Jimenez
Hospitales Universitarios Virgen del Rocío
Hospital Clinico Universitario San Cecilio
Hospital Universitario de Valme
Hospital de Poniente
Hospital Costa del Sol
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* They agree to participate in the study by signing an informed consent form
Exclusion criteria
* Decline to participate in the study * Patients living 6 months or less in the reference health area * Patients with active malignant tumors
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical improvement (risk profile) | 12 months | Percentage of patients reducing annual mortality risk profile according to ESC/ERS Clinical Practice Guidelines 2015 Risk Stratification. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Risk stratification variables | Basaline | Percentage of clinical tests that have been used to include study treatment. |
| Events | 12 months | Incidence of events in follow-up: admission for worsening pulmonary hypertension; need for systemic prostacyclins; unscheduled admission for any cause; death related to pulmonary hypertension; death from any cause. |
Countries
Spain
Contacts
Primary ContactRafael Bravo Marqués, PhD, MD
Outcome results
None listed